People choose to volunteer for a variety of reasons. For some it offers the chance to give something back to the community or make a difference to the people around them. For others it provides an More
Connie’s career encompasses three different industries during periods of rapid growth and evolution: commercial banking, biotechnology and social innovation. While Connie was on the executive team at IDEC Pharmaceuticals, the company grew from a 100-person development stage enterprise to a fully integrated biopharmaceutical company with 1,000 employees. IDEC developed Rituxan, the first monoclonal antibody to receive FDA approval to treat cancer as well as Zevalin, the first radioimmunotherapy for cancer approved by the FDA. Partnered with Genentech and Roche, worldwide sales of Rituxan are now over $7B annually. After a merger-of-equals with Biogen in 2004, Connie retired from Biogen Idec five years later. Prior to entering the biotech industry, Connie held various general management, marketing and human resources roles at Wells Fargo Bank. Connie has been a lifelong volunteer and nonprofit board member at the local, national and international level. She has been an agent for strategic change and a champion for catalytic philanthropy and impact investing in her roles on foundation and regional grant maker boards. Connie earned B.A. and M.B.A. degrees from Stanford University. She also serves on the Boards of Halozyme Therapeutics and Artelo Biosciences.